16/05/2018 16:30:12

Bavarian Nordic to Host First Quarter 2018 Results Conference Call

Related content
19 Sep - 
Bavarian Nordic Delivers Smallpox Vaccine to England in..
18 Sep - 
Bavarian Nordic Announces Initiation of Phase 2 Trial E..
21 Aug - 
Importance of Smallpox Vaccination Highlighted in Biopr..
Related debate
24 Sep - 
tak
24 Sep - 
https://www.helsingordagblad.dk/2018/03/24/ny-fabrik-go..
24 Sep - 
De har sagt det mange gange - senest under præsentation..

COPENHAGEN, Denmark -

May 16

, 201

8 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at https://bit.ly/2KzQlN2.

To join the Q&A session dial one of the following numbers and state the participant code 8332812: Denmark: +45 35 15 81 21, UK: +44 (0) 330 336 9411, USA: +1 323-794-2551.

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43

U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
21 Sep
BAVA
Det er ikke så svært at finde grunden. Rigtig ofte vinder hedgefondene på deres shorts. Nogle gange ..
9
19 Sep
BAVA
Hej alle, Nu er videoen oppe fra Investordagen i går. Den kan ses her: https://getvisualtv.net..
9
21 Sep
BAVA
Jeg havde en frygt for, at BAVA kunne møde modstand her ved 175, og det ser meget aktuelt ud. Ved si..
5
24 Sep
BAVA
Hvis man tager CARs analyse fra i dag har de følgende sammensætning af pipelinens værdi:   SOTP of D..
4
24 Sep
BAVA
Bavarian - hvad er deres pipeline værd .... kort før Prostvac resultatet blev annonceret med resulta..
4
21 Sep
BAVA
Du har da ret i, at når Wace fonden for nyligt har øget i Bavarian, er det ikke sket til 250. Men je..
4
24 Sep
BAVA
Carnegie har genoptaget dækning af Bavarian Nordic med anbefalingen køb og et kursmål på 245 kr. Det..
3
20 Sep
BAVA
BAVARIAN NORDIC LEVERER KOPPEVACCINER TIL ENGLANDS BEREDSKAB I FORBINDELSE MED AKTUELLE TILFÆLDE AF ..
3
20 Sep
BAVA
Det ser ud til den har nået bunden i denne omgang og kører modsat - gennemgangen på aktionærforening..
3
19 Sep
BAVA
Bavarian Nordic leverer koppevacciner til Englands beredskab i forbindelse med aktuelle tilfælde af ..
3

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Diagnostic Superiority and Equivalence to Biopsy: a Study Confirms the Clinical Value of ShearWave® Elastography (SWE™) for the Non-Invasive Evaluation of Liver Fibrosis
2
Payment Security Compliance drops for the first time in six years, states Verizon’s 2018 Payment Security Report
3
PCG Advisory Group Co-Sponsored Family Office Event Presented by Morgan Creek Capital and BlockWorks Group
4
Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress
5
Recall Studios Will Host Shareholder Call, Tuesday, September 25th at 11am EST

Related stock quotes

Bavarian Nordic A/S 176,40 0.1% Stock price increasing
Bavarian Nordic Ord Shs 176.40 0.1% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 September 2018 16:50:54
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB4 - 2018-09-25 17:50:54 - 2018-09-25 16:50:54 - 1000 - Website: OKAY